Phase 1TerminatedAge-related condition
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination With Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes
- Sponsor
- Aprea Therapeutics (Industry)
- Enrollment
- 4 enrolled
- Conditions
- MDS; Myelodysplastic Syndromes
- Interventions
- APR-548 + Azacitidine
- Ages
- adults, older adults
- Registry
- NCT04638309
Full record on ClinicalTrials.gov
From the registry
Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.
Primary outcomes
- To Investigate the "Number of Participants With Treatment Emergent Adverse Events From Treatment With APR-548 as Monotherapy and in Combination With Azacitidine
History
Last registry update
Results first posted
Primary completion
Started
Registered